Memantine HCl 7 mg (7), 14 mg (7), 21 mg (7), 28 mg (7) 24HR Extended Release Oral Capsule 28 Count Pack
RxNorm 996624
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 996624 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: memantine HCl 7 mg (7), 14 mg (7), 21 mg (7), 28 mg (7) 24HR Extended Release Oral Capsule 28 Count Pack.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Prescribable Name (PSN):
Memantine HCl 7 mg (7), 14 mg (7), 21 mg (7), 28 mg (7) 24HR Extended Release Oral Capsule 28 Count Pack
(Atom ID: 12675858)
Synonym (SY):
Memantine hydrochloride titration pack 28; 7MG/14MG/21MG/28MG Extended Release Oral Capsule
(Atom ID: 6356943)
Generic Pack (GPCK):
{7 (24 HR memantine hydrochloride 14 mg Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 21 mg Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 28 mg Extended Release Oral Capsule) / 7 (24 HR memantine hydrochloride 7 mg Extended Release Oral Capsule) } Pack
(Atom ID: 12372859)
Patient Education
Memantine
Memantine is used to treat the symptoms of Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Memantine is in a class of medications called NMDA receptor antagonists. It works by decreasing abnormal activity in the brain. Memantine may improve the ability to think and remember or may slow the loss of these abilities in people who have AD. However, memantine will not cure AD or prevent the loss of these abilities at some time in the future.
[Learn More]
* Please review the disclaimer below.